TICKERNERD
Menu
DCTHDCTHHealthcare · Medical Devices

DCTH Stock Forecast: Delcath Systems, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$15
−2.26% on the day

The 5 Wall Street analysts covering Delcath Systems, Inc. hold a median 12-month price target of $22 — +45.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 8 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$521.6M
Ticker Nerd rank
94 / 100
Median analyst target
$22
Analysts covering
5
Total return, dividends reinvested
1W
+23.7%
1M
+12.5%
YTD
+49.7%
1Y
+48.4%
From 52W high
−2.3%
From 52W low
+84.6%
$8
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DCTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Delcath Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
100
Value
99
Revisions
92
Volatility
78
Accruals
77
Momentum
55
Size
53
Issuance
40
Growth
36

Quality (100): The business earns solid, repeatable profits on what it owns.

Growth (36): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own Delcath Systems, Inc. — and when they’d sell — is the membership.

Wall Street

DCTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DCTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26DCTHHigh $30Median $22Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $21Median $22High $30

The green dot is the last close — the median target sits +45.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Feb 2026BTIGMaintainsBuy$23 → $19
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
5 Nov 2025Stephens & Co.MaintainsOverweight—
4 Nov 2025BTIGReiteratesBuy—
21 Oct 2025Canaccord GenuityMaintainsBuy—
20 Oct 2025HC Wainwright & Co.MaintainsBuy—
7 Aug 2025HC Wainwright & Co.MaintainsBuy—
23 June 2025Stephens & Co.ReiteratesOverweight—
23 May 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025HC Wainwright & Co.MaintainsBuy—
17 Jan 2025Craig-HallumMaintainsBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024Canaccord GenuityMaintainsBuy$21
18 Oct 2024HC Wainwright & Co.ReiteratesBuy$22
6 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024Stephens & Co.ReiteratesOverweight—
28 June 2024Craig-HallumInitiatesBuy—
15 May 2024HC Wainwright & Co.MaintainsBuy—
14 May 2024Stephens & Co.InitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

DCTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Delcath Systems, Inc. (DCTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1511.0×

Cheaper than 1% of US stocks

Price / sales
5.5×

Cheaper than 23% of US stocks

Price / book
4.7×

Cheaper than 23% of US stocks

EV / EBITDA
−293.3×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
20.6%

Higher than 71% of US stocks

Earnings growth (YoY)
−1.1%

Higher than 34% of US stocks

Gross margin
85.1%

Higher than 94% of US stocks

Operating margin
8.2%

Higher than 61% of US stocks

Net margin
0.6%

Higher than 48% of US stocks

Returns & dividend
Return on equity
0.5%

Higher than 45% of US stocks

Return on assets
−0.9%

Higher than 40% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DCTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
DCTHDelcath Systems, Inc.$521.6M
94
VREXVarex Imaging Corp.$520.2M
87
CTKBCytek Biosciences, Inc.$542.4M
59
NPCENeuroPace, Inc.$499.3M
87
KIDSOrthoPediatrics Corp.$571.0M
64
CERSCerus Corp.$451.4M
94
SIShoulder Innovations, Inc.$427.0M
18
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DCTH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest DCTH news & analysis

Delcath: Temporary Headwinds Are Fading While Larger Opportunities Approach

Seeking Alpha · 7 Aug 2026positive

Delcath Systems reported strong second-quarter revenue and earnings, with its shares surging as a result. The article notes that Q3 seasonality is expected to be less pronounced in 2026, which is expected to keep growth robust in the second half of the year.

Why it matters — DCTH watchers would care because the article suggests that recent quarterly headwinds are fading and that the company's growth is expected to remain strong through the second half of 2026.

Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Delcath Systems held its Q2 2026 earnings call, during which management discussed the company's quarterly financial results and business developments.

Why it matters — DCTH watchers look to earnings calls for management's commentary on commercial progress, pipeline updates, and financial health.

Delcath Systems Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Delcath Systems reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier. The company attributed growth to higher HEPZATO KIT sales, which supported continued commercial expansion and investment in clinical programs beyond metastatic uveal melanoma.

Why it matters — The reported year-over-year revenue gain for HEPZATO KIT signals ongoing commercial traction and broader clinical development, relevant to DCTH watchers tracking the company's growth trajectory.

Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Delcath Systems reported quarterly earnings of $0.07 per share, surpassing the Zacks Consensus Estimate of a $0.16 per share loss. This matches its earnings of $0.07 per share from a year ago.

Why it matters — The company beat analyst expectations for the quarter, which would be of interest to DCTH watchers tracking its financial performance.

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

Business Wire · 6 Aug 2026positive

Delcath Systems reported financial results for the second quarter ended June 30, 2026, with total revenue of $29.1 million compared with $24.2 million in the second quarter of 2025. HEPZATO KIT revenue was $27.1 million, up from $22.5 million in the year-ago quarter.

Why it matters — The quarterly results show year-over-year growth in total revenue and HEPZATO KIT sales, offering DCTH watchers a current view of the company's commercial performance.

FAQ

Frequently asked questions about DCTH stock

What is the DCTH stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Delcath Systems, Inc. have a median 12-month price target of $22, with estimates ranging from $21 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DCTH stock a buy right now?

Of the 5 analysts covering Delcath Systems, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Delcath Systems, Inc. 94 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DCTH?

As at 8 Aug 2026, Delcath Systems, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).

Will DCTH stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +45.5% from the last close, and Ticker Nerd's factor model ranks Delcath Systems, Inc. 94 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DCTH stock forecast for 2030?

No analyst covering Delcath Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $30 over the next 12 months.

How has DCTH stock performed over the past year?

Delcath Systems, Inc. returned +48.4% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Delcath Systems, Inc. do?

Delcath Systems Inc. is a medical device company focused on providing treatment options for primary and metastatic liver cancers through its innovative technologies.

What is the latest news on DCTH?

The most recent item we track (Seeking Alpha, 7 Aug 2026): "Delcath: Temporary Headwinds Are Fading While Larger Opportunities Approach". Delcath Systems reported strong second-quarter revenue and earnings, with its shares surging as a result. The article notes that Q3 seasonality is expected to be less pronounced in 2026, which is expected to keep growth robust in the second half of the year.

Company

About Delcath Systems, Inc.

Delcath Systems Inc. is a medical device company focused on providing treatment options for primary and metastatic liver cancers through its innovative technologies. Central to their product offerings is the percutaneous hepatic perfusion (PHP) system, which enables targeted delivery of high-dose chemotherapy directly to the liver. This approach aims to maximize impact on cancer cells while minimizing systemic exposure and related side effects. Delcath Systems Inc. operates primarily within the healthcare sector, impacting the medical device and oncology industries. The company engages with hospitals, medical professionals, and patients, contributing to evolving treatment protocols for liver cancer. By developing interventional medical solutions, Delcath Systems Inc. plays a significant role in advancing targeted cancer therapies and enhancing the arsenal of available tools in oncology. Headquartered in New York, the company is part of a growing movement towards personalized and precision medicine, seeking to improve patient outcomes through targeted therapeutic interventions.

CEO Mr. Gerard J. Michel MBA, MS · 156 employees · United States · https://www.delcath.com